LBA18_PR - Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
Publication/Presentation Date
10-2018
Volume
29
Issue
8
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article
COinS